{
    "id": 1159,
    "fullName": "ERBB2 negative",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "ERBB2 (HER2) negative indicates a lack of the ERBB2 (HER2) gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2064,
        "geneSymbol": "ERBB2",
        "terms": [
            "ERBB2",
            "CD340",
            "HER-2",
            "HER-2/neu",
            "HER2",
            "MLN 19",
            "NEU",
            "NGL",
            "TKR1"
        ]
    },
    "variant": "negative",
    "createDate": "07/25/2014",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6540,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Seribantumab (MM-12) and Aromasin (exemestane) combination treatment resulted in a 74% decrease in risk of progression (HR 0.26) and a a 59% decrease in risk of death (HR 0.436) compared to exemestane alone in ERBB2-negative, hormone receptor positive breast cancer patients (AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer, May 2016, Abstract # A14).",
            "molecularProfile": {
                "id": 1184,
                "profileName": "ERBB2 negative"
            },
            "therapy": {
                "id": 4141,
                "therapyName": "Exemestane + Seribantumab",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5690,
                    "pubMedId": null,
                    "title": "Identification of heregulin expression as a driver of a difficult-to-treat cancer phenotype and development of a prospective companion diagnostic for the heregulin-ErbB3 targeting drug seribantumab",
                    "url": "http://files.shareholder.com/downloads/AMDA-IWDM2/2127694404x0x892308/7BACAE03-69E0-423A-A4D5-8A19EFED7AE1/MM-121_AACR_Precision_Medicine_Poster_11May2016_FINAL.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1065,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Cyramze (ramucirumab) in combination with Taxotere (docetaxel) did not improve clinical outcomes in ERBB2 (HER2)-negative breast cancer patients (PMID: 25185099).",
            "molecularProfile": {
                "id": 1184,
                "profileName": "ERBB2 negative"
            },
            "therapy": {
                "id": 1423,
                "therapyName": "Docetaxel + Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 665,
                    "pubMedId": 25185099,
                    "title": "Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25185099"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10434,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, combination of Navelbine (vinorelbine) and Nexavar (sorafenib) resulted in a response rate of 30% (8/27), median progression free survival of 5.7 months, and a clinical benefit rate (absence of disease progression at 6 months) of 48% (13/27) in patients with ERBB2 (HER2)-negative metastatic breast cancer (PMID: 27992451).",
            "molecularProfile": {
                "id": 1184,
                "profileName": "ERBB2 negative"
            },
            "therapy": {
                "id": 2357,
                "therapyName": "Sorafenib + Vinorelbine",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8447,
                    "pubMedId": 27992451,
                    "title": "Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27992451"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10444,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, adding Avastin (bevacizumab) to adjuvant chemotherapy did not significantly improve overall survival (HR=0.93, p=0.52) in patients with early triple-negative breast cancer (PMID: 27993816).",
            "molecularProfile": {
                "id": 1807,
                "profileName": "ERBB2 neg ESR1 neg PGR neg"
            },
            "therapy": {
                "id": 667,
                "therapyName": "Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8459,
                    "pubMedId": 27993816,
                    "title": "Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27993816"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5057,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, triple-receptor negative breast cancer cell lines positive for Hhat demonstrated resistance to RU-SKI 43 treatment in culture (PMID: 25889650).",
            "molecularProfile": {
                "id": 20222,
                "profileName": "ERBB2 neg ESR1 neg HHAT pos PGR neg"
            },
            "therapy": {
                "id": 3744,
                "therapyName": "RU-SKI 43",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4868,
                    "pubMedId": 25889650,
                    "title": "Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25889650"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7139,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with LY3039478 resulted in partial response in one patient with ER-positive, PR-positive, ERBB2 (HER2)-negative breast cancer (J Clin Oncol 33, 2015 (suppl; abstr 2533)).",
            "molecularProfile": {
                "id": 24496,
                "profileName": "ERBB2 neg ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 2958,
                "therapyName": "LY3039478",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5879,
                    "pubMedId": null,
                    "title": "First-in-human study of LY3039478, a Notch signaling inhibitor in advanced or metastatic cancer",
                    "url": "http://meetinglibrary.asco.org/content/144588-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8747,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).",
            "molecularProfile": {
                "id": 26426,
                "profileName": "ERBB2 neg MET pos"
            },
            "therapy": {
                "id": 838,
                "therapyName": "Onartuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6730,
                    "pubMedId": null,
                    "title": "METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).",
                    "url": "http://meetinglibrary.asco.org/content/147779-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10904,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).",
            "molecularProfile": {
                "id": 26426,
                "profileName": "ERBB2 neg MET pos"
            },
            "therapy": {
                "id": 5676,
                "therapyName": "Fluorouracil + Leucovorin + Onartuzumab + Oxaliplatin",
                "synonyms": "Onartuzumab + FOLFOX"
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8918,
                    "pubMedId": 27918764,
                    "title": "Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27918764"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8745,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).",
            "molecularProfile": {
                "id": 26426,
                "profileName": "ERBB2 neg MET pos"
            },
            "therapy": {
                "id": 629,
                "therapyName": "Rilotumumab",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6729,
                    "pubMedId": null,
                    "title": "Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal juncti",
                    "url": "http://meetinglibrary.asco.org/content/147255-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10905,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).",
            "molecularProfile": {
                "id": 26426,
                "profileName": "ERBB2 neg MET pos"
            },
            "therapy": {
                "id": 5676,
                "therapyName": "Fluorouracil + Leucovorin + Onartuzumab + Oxaliplatin",
                "synonyms": "Onartuzumab + FOLFOX"
            },
            "indication": {
                "id": 4914,
                "name": "esophagus adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8918,
                    "pubMedId": 27918764,
                    "title": "Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27918764"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8744,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).",
            "molecularProfile": {
                "id": 26426,
                "profileName": "ERBB2 neg MET pos"
            },
            "therapy": {
                "id": 629,
                "therapyName": "Rilotumumab",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6729,
                    "pubMedId": null,
                    "title": "Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal juncti",
                    "url": "http://meetinglibrary.asco.org/content/147255-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8746,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).",
            "molecularProfile": {
                "id": 26426,
                "profileName": "ERBB2 neg MET pos"
            },
            "therapy": {
                "id": 838,
                "therapyName": "Onartuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6730,
                    "pubMedId": null,
                    "title": "METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).",
                    "url": "http://meetinglibrary.asco.org/content/147779-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8862,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of RO4929097 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone (PMID: 27556950).",
            "molecularProfile": {
                "id": 26477,
                "profileName": "ERBB2 neg ERBB2 pos"
            },
            "therapy": {
                "id": 4840,
                "therapyName": "Paclitaxel + RO4929097",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6775,
                    "pubMedId": 27556950,
                    "title": "HER2 expression identifies dynamic functional states within circulating breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27556950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8861,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of LY411575 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone (PMID: 27556950).",
            "molecularProfile": {
                "id": 26477,
                "profileName": "ERBB2 neg ERBB2 pos"
            },
            "therapy": {
                "id": 4841,
                "therapyName": "LY411575 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6775,
                    "pubMedId": 27556950,
                    "title": "HER2 expression identifies dynamic functional states within circulating breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27556950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3634,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK-2206 inhibited growth and colony formation of a triple negative human breast cancer cell line harboring AKT E17K in culture and inhibited tumor growth in xenograft models (PMID: 26351323).",
            "molecularProfile": {
                "id": 26602,
                "profileName": "AKT1 E17K ERBB2 neg ESR1 neg PGR neg"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3912,
                    "pubMedId": 26351323,
                    "title": "Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10855,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BETd-246 induced degradation of BET proteins, resulted in tumor regression in patient-derived xenograft models of treatment-resistant, PGR-negative, ERBB2 (HER2)-negative breast cancer harboring ESR1 E380Q (PMID: 28209615).",
            "molecularProfile": {
                "id": 27813,
                "profileName": "ERBB2 neg ESR1 E380Q PGR neg"
            },
            "therapy": {
                "id": 5603,
                "therapyName": "BETd-246",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8792,
                    "pubMedId": 28209615,
                    "title": "Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28209615"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2660,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, strongly ESR1 (ER)-positive patients with ERBB2 (HER2)-negative breast cancer had a decreased response to the combination of Avastin (bevacizumab), docetaxel, fluorouracil, epirubicin, and cyclophosphamide compared to ESR1-negative and weakly positive patients, with complete response (CR) in 6% (14/232) compared to an overall CR of 22% (87/388) (PMID: 25975632).",
            "molecularProfile": {
                "id": 27929,
                "profileName": "ERBB2 neg ESR1 pos"
            },
            "therapy": {
                "id": 2988,
                "therapyName": "Bevacizumab + Cyclophosphamide + Docetaxel + Epirubicin + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3374,
                    "pubMedId": 25975632,
                    "title": "Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25975632"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11104,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Abemaciclib (LY2835219) and Faslodex (fulvestrant) combination therapy resulted in improved median progression free survival (16.4 vs 9.3 months) and overall response rate (48.1% vs 21.3%) compared to placebo in patients with treatment refractory hormone receptor positive, Erbb2 (Her2) negative breast cancer (PMID: 28580882).",
            "molecularProfile": {
                "id": 27929,
                "profileName": "ERBB2 neg ESR1 pos"
            },
            "therapy": {
                "id": 5859,
                "therapyName": "Abemaciclib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9173,
                    "pubMedId": 28580882,
                    "title": "MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28580882"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11224,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Abemaciclib (LY2835219) and Faslodex (fulvestrant) combination therapy resulted in improved median progression free survival (16.4 vs 9.3 months) and overall response rate (48.1% vs 21.3%) compared to placebo in patients with treatment refractory hormone receptor positive, Erbb2 (Her2) negative breast cancer (PMID: 28580882).",
            "molecularProfile": {
                "id": 27930,
                "profileName": "ERBB2 neg PGR pos"
            },
            "therapy": {
                "id": 5859,
                "therapyName": "Abemaciclib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60077,
                "name": "progesterone-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9173,
                    "pubMedId": 28580882,
                    "title": "MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28580882"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12381,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of MK2206 to Arimidex (anastrozole) treatment did not further induce apoptosis and resulted in no pathologic complete response (0/13) in estrogen receptor-positive, Erbb2 (Her2)-negative breast cancer patients harboring PIK3CA mutations (PMID: 28874413; NCT01776008).",
            "molecularProfile": {
                "id": 28721,
                "profileName": "ERBB2 neg ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 4188,
                "therapyName": "Anastrozole + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10361,
                    "pubMedId": 28874413,
                    "title": "A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28874413"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1184,
            "profileName": "ERBB2 negative",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1807,
            "profileName": "ERBB2 neg ESR1 neg PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 10545,
            "profileName": "BRCA1 mut ERBB2 neg ESR1 neg PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 10713,
            "profileName": "BRCA1 wild-type ERBB2 neg ESR1 neg PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 10714,
            "profileName": "BRCA1 dec exp ERBB2 neg ESR1 neg PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 10716,
            "profileName": "ERBB2 neg ESR1 neg PALB2 dec exp PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14067,
            "profileName": "AKT1 E17K ERBB2 neg ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14276,
            "profileName": "ERBB2 neg ESR1 neg NOTCH1 V2249* PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14277,
            "profileName": "ERBB2 neg ESR1 neg NOTCH1 P2462fs PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14279,
            "profileName": "ERBB2 neg ESR1 neg NOTCH1 mut PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 15930,
            "profileName": "ERBB2 neg ESR1 neg NOTCH1 S2449fs PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17702,
            "profileName": "NOTCH1 rearrange ERBB2 negative ESR1 negative PGR negative",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17812,
            "profileName": "NOTCH2 rearrange ERBB2 neg ESR1 neg PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17813,
            "profileName": "ERBB2 neg ESR1 neg NOTCH1 wild-type PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18589,
            "profileName": "ERBB2 neg ERBB3 pos ESR1 neg PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18832,
            "profileName": "ERBB2 neg ESR1 neg GPNMB over exp PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19847,
            "profileName": "ERBB2 neg ESR1 neg PGR neg PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20222,
            "profileName": "ERBB2 neg ESR1 neg HHAT pos PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20270,
            "profileName": "ERBB2 neg ESR1 neg PGR neg PIK3CA wild-type PTEN del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21968,
            "profileName": "ERBB2 neg ESR1 neg PGR neg PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21970,
            "profileName": "ERBB2 neg ESR1 neg PGR neg PIK3CA wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24496,
            "profileName": "ERBB2 neg ESR1 pos PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26426,
            "profileName": "ERBB2 neg MET pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26477,
            "profileName": "ERBB2 neg ERBB2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26602,
            "profileName": "AKT1 E17K ERBB2 neg ESR1 neg PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26900,
            "profileName": "CCND1 pos ERBB2 neg ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26908,
            "profileName": "AR pos ERBB2 neg ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26909,
            "profileName": "AR pos ERBB2 neg ESR1 neg PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27813,
            "profileName": "ERBB2 neg ESR1 E380Q PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27913,
            "profileName": "BRCA1 mut ERBB2 neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27914,
            "profileName": "BRCA2 mut ERBB2 neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27929,
            "profileName": "ERBB2 neg ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27930,
            "profileName": "ERBB2 neg PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28721,
            "profileName": "ERBB2 neg ESR1 pos PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31228,
            "profileName": "ERBB2 neg ESR1 pos PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31229,
            "profileName": "ERBB2 neg PGR pos PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31230,
            "profileName": "ERBB2 neg ESR1 pos PGR pos PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31231,
            "profileName": "ERBB2 neg ESR1 pos PTEN mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31232,
            "profileName": "ERBB2 neg PGR pos PTEN mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31233,
            "profileName": "ERBB2 neg ESR1 pos PGR pos PTEN mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31235,
            "profileName": "ERBB2 neg ESR1 pos PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31236,
            "profileName": "ERBB2 neg PGR pos PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31237,
            "profileName": "ERBB2 neg ESR1 pos PGR pos PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}